BRISTOL-MYERS SQUIBB COMPANY Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $57.85 per share as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-02-11
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $57.85.
- 2024-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $59.02.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $57.34.
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $55.25.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $57.85 10-K · filed 2026-02-11 |
| 2024-12-31 | $59.02 10-K · filed 2025-02-12 |
| 2023-12-31 | $57.34 10-K · filed 2024-02-13 |
| 2022-12-31 | $55.25 10-K · filed 2023-02-14 |
| 2021-12-31 | $53.00 10-K · filed 2022-02-09 |
| 2020-12-31 | $50.25 10-K · filed 2021-02-10 |
| 2019-12-31 | $48.08 10-K · filed 2020-02-24 |
| 2016-12-31 | $21.02 10-K · filed 2017-02-21 |
| 2015-12-31 | $21.61 10-K · filed 2016-02-12 |
| 2014-12-31 | $22.29 10-K · filed 2015-02-13 |
| 2013-12-31 | $22.88 10-K · filed 2014-02-14 |
| 2012-12-31 | $23.21 10-K · filed 2013-02-15 |
| 2011-12-31 | $27.04 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |